IVAC MUTANOME Phase I Clinical Trial
Trial status:Study Complete
Study Identifier:
RB_0004-01
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech RNA Pharmaceuticals GmbH
Study Complete
Trial details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
18 - 99 Years
Estimated Trial Date
Dec 2013 - Feb 2017
Protocol summary
Clinical first-in-human study evaluating the safety, tolerability and immunogenicity of intra-nodal administration of a personalized vaccination with IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002 vaccine in patients with advanced melanoma
Trial locations
Location
Status
Location
Medizinische Universität Wien
Wien, AT-Wien, Austria, 1090
Status
Location
Hautklinik und Poliklinik Universitätsmedizin der Johannes-Gutenberg Universität Mainz
Mainz, Germany, 55131
Status
Location
Klinik für Dermatologie, Venerologie und Allergologie UMM - Universitätsmedizin Mannheim Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität Heidelberg
Mannheim, Germany, 68167
Status